ArticleCancers2026

Post-Recurrence Outcomes Associated with a Bevacizumab-Containing First-Recurrence Strategy in Glioblastoma: A Propensity-Weighted Single-Center Cohort Study with Competing-Risk Analysis.

Enes Yeşilbaş et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.